Elsevier

Life Sciences

Volume 58, Issue 12, 16 February 1996, Pages PL231-PL239
Life Sciences

Pharmacology letter accelerated communication
Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters

https://doi.org/10.1016/0024-3205(96)00052-5Get rights and content

Abstract

We have synthesized several derivatives of dl-threo-methylphenidate (Ritalin) bearing substituents on the phenyl ring. IC50 values for binding of these compounds to rat brain monoamine transporters were assessed using [3H]WIN 35,428 (striatal membranes, dopamine transporters, DAT), [3H]nisoxetine (frontal cortex membranes, norepinephrine transporters, NET) and [3H]paroxetine (brain stem membranes, 5HT transporters, 5HTT). Affinities (1/Ki) decreased in the order: DAT > NET ⪢ 5HTT. Substitution at the para position of dl-threo-methylphenidate generally led to retained or increased affinity for the dopamine transporter (bromo > iodo > methoxy > hydroxy). Substitution at the meta position also increased affinity for the DAT (m-bromo > methylphenidate; m-iodo-p-hydroxy > p-hydroxy). Substitution at the ortho position with bromine considerably decreased affinity. Similar IC50 values for binding of o-bromomethylphenidate to the dopamine transporter were measured at 0, 22 and 37 degrees. N-Methylation of the piperidine ring of methylphenidate also considerably reduced affinity. The dl-erythro isomer of obromomethylphenidate did not bind to the DAT (IC50 > 50,000 nM). Affinities at the dopamine and norepinephrine transporters for substituted methylphenidate derivatives were well correlated (r2 = 0.90). Abilities of several methylphenidate derivatives to inhibit [3H]dopamine uptake in striatal synaptosomes corresponded well with inhibition of [3H]WIN 35, 428 binding. None of the compounds examined exhibited significant affinity to dopamine D1 or D2 receptors (IC50 > 500 or 5,000 nM, respectively), as assessed by inhibition of binding of [3H]SCH 23390 or [123I]epidepride, respectively, to striatal membranes.

References (40)

  • D. Pan et al.

    Eur. J. Pharmacol.

    (1994)
  • M.C. Ritz et al.

    Life Sci.

    (1990)
  • H.M.L. Davies et al.

    Eur. J. Pharmacol.

    (1993)
  • R.B. Rothman

    Life Sci.

    (1990)
  • R.B. Rothman et al.

    Life Sci.

    (1993)
  • H.M. Deutsch et al.

    Life Sci.

    (1994)
  • C. Xu et al.

    Biochem. Pharmacol.

    (1995)
  • J.W. Boja et al.

    Eur. J. Pharmacol.

    (1991)
  • M.M. Schweri et al.

    J. Neurochem.

    (1985)
  • R.J. Chiarello et al.

    Arch. Gen. Psychiat.

    (1987)
  • M.C. Ritz et al.

    Science

    (1987)
  • Y.S. Ding et al.

    J. Nucl. Med.

    (1995)
  • S.J. Gatley et al.

    Eur. J. Pharmacol.

    (1995)
  • N.D. Volkow et al.

    J. Nucl. Med.

    (1995)
  • M. Laruelle et al.

    Synapse

    (1993)
  • R.B. Innis et al.
  • N.D. Volkow et al.

    Arch. Gen. Psychiat.

    (1995)
  • L. Panizzon

    Helv. Chim. Acta

    (1944)
  • K.S. Patrick et al.

    J. Med. Chem.

    (1981)
  • K.S. Patrick et al.

    J. Pharmacol. Exp. Ther.

    (1987)
  • Cited by (185)

    • Effects of methylphenidate after a long period of discontinuation include changes in exploratory behavior and increases brain activities of Na<sup>+</sup>,K<sup>+</sup>-ATPase and acetylcholinesterase

      2022, Neurobiology of Learning and Memory
      Citation Excerpt :

      Its neuropharmacological profile is similar to that of cocaine or amphetamine, which it is thought to indirectly increase dopamine (DA) levels by blocking the dopamine active transporter (DAT) (Challman & Lipsky, 2000; Schmeichel & Berridge, 2013). Moreover, MPH has an affinity for blocking norepinephrine (NE) and serotonin transporters, although less than for DA (Gatley, SJ; Pan, D; Chen, R; Chaturvedi, G; Ding, 1996; Hannestad et al., 2010; Kuczenski & Segal, 1997). Treatment with MPH is usually well tolerated and its efficacy in reducing symptoms of ADHD is consistently reported (Oh et al., 2018; Sudnawa et al., 2018), but due to the large increase in rates of MPH prescriptions over the last years and its pharmacological profile and ease of access, researchers have also been quite concerned about the increased incidence of MPH misuse (Johnston, LD; O’Malley, PM; Bachman, JG; Schullenberg, 2011a, 2011b).

    View all citing articles on Scopus
    View full text